n-acetylcysteine a safe antidote for cysteine glutathione deficiency Clinical Applications Efficacy of intravenous N acetylcysteine

3), suggesting that there is a therapeutic window for co-treatment

Largest reductions (18-20%) occurred in the high-dose group after 1 and 2 weeks Combined dose groups significantly reduced the ratio by 14% after 1 and 2 weeks The decreases observed in oxidized:reduced GSH as a result of oral liposomal GSH supplementation are likely indicative of a general systemic reduction in oxidative stress levels. Plasma levels of 8-isoprostane (a marker of oxidative stress) decreased after liposomal glutathione supplementation

Nat Nanotechnol (2016) 11(10):8909

doi: 10.3389/fcvm.2022.895792 5

Ingredients: Water, Betaine, Diglycerin, Butylene Glycol, Niacinamide, 1,2-Hexanediol, PEG-60 Hydrogenated Castor Oil, Lilium Candidum Callus Culture Extract, Carbomer, Arginine, Ethylhexylglycerin, Adenosine, Sodium Hyaluronate, Disodium EDTA, Hydroxyethylcellulose, Malt Extract, Glycerin, Prunus Persica (Peach) Fruit Extract, Crataegus Cuneata Fruit Extract, Xanthan Gum, Pyrus Communis (Pear) Fruit Extract, Dipotassium Glycyrrhizate, Magnolia Officinalis Bark Extract, Musa Sapientum (Banana) Fruit Extract, Hedera Helix (Ivy) Extract, Vanilla Planifolia Fruit Extract, Rosa Damascena Callus Culture Extract(30ppm), Glycine Soja (Soybean) Oil, Phosphatidylcholine, Fructan, Caprylyl Glycol, Hydrogenated Lecithin, Palmitoyl Tripeptide-5, Sodium Phosphate, Sodium Ascorbyl Phosphate, PEG-40 Hydrogenated Castor Oil, PPG-26-Buteth-26, Polysorbate 20, Lecithin, Palmitoyl Tetrapeptide-7, Acetyl Octapeptide-3, Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1, Acetyl Hexapeptide-8, Copper Tripeptide-1

Jewell et al., 2015) via the small GTPase ADP-ribosylation factor 1 (ARF1) (Jewell et al., 2015)